Mesothelioma Clinical Trials

Quick Answer

Mesothelioma clinical trials test new immunotherapies (checkpoint inhibitors, CAR-T cells), targeted therapies, vaccine approaches, and combination treatments. Find trials at ClinicalTrials.gov or through NCI-designated cancer centers. Most trials require enrollment at an NCI center.

Mesothelioma clinical trials are critical for advancing treatment options. Multiple trial types are currently enrolling:

Major Trial Categories

• Immune checkpoint inhibitor combinations — building on the 2020 nivolumab + ipilimumab approval. Trials include pembrolizumab combinations, durvalumab, atezolizumab.
• CAR-T cell therapy — engineering patient T-cells to target mesothelioma antigens (mesothelin). Multiple Phase 1/2 trials at MSK, UPenn, others.
• Targeted therapy — drugs targeting specific mutations in mesothelioma (BAP1, NF2, CDKN2A).
• Tumor treating fields (TTFields / Optune Lua) — already FDA-approved for mesothelioma (May 2019). Continued trials extending indications.
• Vaccine approaches — therapeutic mesothelioma vaccines targeting mesothelin or WT-1.
• Cytoreductive surgery + HIPEC variations — for peritoneal mesothelioma.

How to Find Trials

1. **ClinicalTrials.gov** — federal registry of all US clinical trials. Search 'mesothelioma' for active trials.

2. **NCI Cancer Therapy Evaluation Program (CTEP)** — supports many trials.

3. **Mesothelioma Applied Research Foundation** — patient-friendly trial-matching service.

4. **NCI-designated cancer centers** run most trials. Reach out directly.

Eligibility

Most mesothelioma trials have specific eligibility criteria — disease stage, prior treatment history, performance status, organ function, biomarker testing. Your treating oncologist can refer you to applicable trials.